Cormorant Asset Management Fully Exits Arcellx Stake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Source: Fool
- Complete Liquidation: Cormorant Asset Management disclosed on February 17, 2026, that it sold 775,000 shares of Arcellx for approximately $63.63 million, fully liquidating its position and reducing its stake from 4.4% to zero, indicating a complete exit from this investment.
- Market Performance Comparison: Despite Cormorant's exit, Arcellx's stock has surged 60% over the past year, currently priced at $114.51, significantly outperforming the S&P 500's roughly 19% gain during the same period, reflecting strong market confidence in its future potential.
- Company Fundamentals: With a market capitalization of $6.7 billion, Arcellx reported $22.3 million in revenue over the last twelve months, but incurred a net loss of $228.9 million, highlighting the high-risk, high-reward nature of its clinical-stage immunotherapy developments targeting cancer.
- Acquisition Potential: Arcellx recently entered into a takeover agreement with Gilead Sciences, valuing the company at approximately $7.8 billion and offering shareholders $115 per share in cash plus potential additional payments tied to future sales milestones, indicating strong interest from larger pharmaceutical companies in its CAR-T cell therapies, which could accelerate development and commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
